Home>
Stocks>
Concord Drugs Ltd

Concord Drugs Ltd (538965)

₹37.87▲3.61%

Get free price alerts. Set up your Free investment account to get Live Prices. >

Overview

Fundamentals

Q3 '23 Results

Technicals

News and Events

Concord Drugs Ltd share Performance

₹35.82
₹38.78
₹37.87
5.41%
Low
Day's Volatility:7.82%
High
2.40%
₹25.56
₹61.5
₹37.87
32.51%
Low
52 Weeks Volatility:94.90%
High
62.40%

Returns %
1 Month Return	-0.19 %
3 Month Return	-9.6 %
1 Year Return	+ 20.87 %

Market Stats
Previous Close	₹₹36.55
Open	₹₹35.82
Volume	₹6,250.00
Upper Circuit	₹-
Lower Circuit	₹-
Market Cap	₹₹36.55Cr

Company Information

Concord Drugs Limited, established in 1995, is one of the most reputable pharmaceutical companies in India that manufactures Finished Pharmaceutical Formulations such as Injectables, Small Volume Parenterals, Dry Powder, Tissue BioAdhesive Tablets, Capsules and Ophthalmic Preparations, and Readytofill Pellets. They specialize in cGMP contract manufacturing and FormulationFillFinish facility providing comprehensive pharmaceutical development and manufacturing services for drug products. Through the use of state-of-the-art technology that ensures the highest level of process integrity and product quality, they strive to provide their customers with an end-to-end solution to their various pharmaceutical product needs. In order to meet the standards set by regulatory bodies, their two manufacturing facilities are designed to comply with the prerequisites of these governing bodies.

Share Price: ₹37.87 per share as on 16 May, 2024 04:01 PM
Market Capitalisation: ₹36.55Cr as of today
Revenue: ₹12.78Cr as on December 2023 (Q4 23)
Net Profit: ₹0.24Cr as on December 2023 (Q4 23)
Listing date: 01 Jan, 0001
Chairperson Name: S Nagi Reddy

Organisation	Concord Drugs Ltd
Headquarters
Industry	Pharmaceuticals
E-voting on shares	Click here to vote

Fundamentals of Concord Drugs Ltd

Insights on Concord Drugs Ltd

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 7.52 Cr → 12.78 Cr (in ₹), with an average increase of 41.2% per quarter
POSITIVE IMPACT
Price Rise
In the last 3 years, Concord Drugs stock has moved up by 3.8%
NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 55.41% of holdings in Mar 2024 quarter
NO EFFECT
Against Peers
In the last 1 year, Zydus Lifesciences Ltd has given 93.2% return, outperforming this stock by 72.3%
NO EFFECT
Retail Holding Unchanged
Retail Investor holdings remained unchanged at 44.59% of holdings in Mar 2024 quarter
NO EFFECT
Against Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 122.3% return, outperforming this stock by 118.4%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 0.56 Cr → -0.24 Cr (in ₹), with an average decrease of 142.9% per quarter